Mammogen Added Diagnostic Veteran to Board
Robert S. Epstein joins the company as it advances its blood-based breast cancer detection assay.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you trust private diagnostics companies to prioritize patient health over their commercial expansion goals?
Newport Beach-based Mammogen has appointed Robert S. Epstein to its Board of Directors as an independent director. The company is currently developing genTRU-breast, a diagnostic platform utilizing RNA biomarker discovery to identify breast cancer through blood samples.
Why it matters
Epstein brings extensive industry experience from his leadership roles at major diagnostics firms, signaling a strategic shift for Mammogen as it moves toward clinical validation.
Epstein served for 13 years on the board of Illumina, a market leader in DNA sequencing hardware and analysis tools. His expertise in diagnostics is expected to support Mammogen's efforts to move its platform from development into prospective clinical validation.
The players
Robert S. Epstein
An experienced diagnostics executive who previously spent 13 years on the Illumina board and currently serves as Chairman of Veracyte and a board member at PinkDx.
Mammogen
A Newport Beach-based startup developing a blood-based diagnostic assay for breast cancer known as genTRU-breast using RNA biomarkers.
The details
Mammogen utilizes RNA biomarker discovery—a process of identifying gene expression patterns in blood—coupled with computational interpretation to develop diagnostic assays. The goal of the genTRU-breast platform is to provide a minimally invasive method for cancer detection, though the company currently remains in the research and validation phase for this technology.
Timeline
October 13, 2026: Robert S. Epstein was appointed to the Board of Directors.
The Tech Race
Mammogen is positioning its genTRU-breast platform to compete in the growing market for non-invasive liquid biopsy diagnostics. The board expansion aligns the company with industry veterans familiar with the scaling challenges of the Illumina genomics sequencing product roadmap.
The company's diagnostic test is not yet available for public clinical use or standard screening workflows. Residents should watch for the upcoming results of the company's prospective clinical validation studies to determine when the assay might reach commercial availability.
The takeaway
Mammogen is shifting focus toward clinical validation and commercialization as it integrates board-level expertise from the broader diagnostics sector. Watch for the company's next prospective clinical readout to verify the diagnostic performance of the genTRU-breast platform.
Further reading
For more on how local firms are advancing clinical diagnostics, explore our Biotech section.
Source note: This article includes information reported by The Manila times.
Live Poll
Do you trust private diagnostics companies to prioritize patient health over their commercial expansion goals?
